Physician profile
Robert L Smith
NPI 1265438436
$4,812.44
in general payments reported to CMS, 2019-2025
25 companies · $958 in 2025
The $958 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $763 · 2021: $313 · 2022: $350 · 2023: $786 · 2024: $1,072 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,326.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $609.55 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $426.24 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $376.68 | 2019-2025 | |
| Abbvie INC. | $355.03 | 2019-2025 | Synthroid, Ubrelvy |
| Lilly USA, LLC | $289.92 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $230.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.56 | 2020-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $207.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $170.22 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company Ltd. | $119.43 | 2022 | |
| Astellas Pharma US INC | $109.63 | 2019-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $67.59 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $57.55 | 2025 | |
| Glaxosmithkline, LLC. | $41.16 | 2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $33.97 | 2023-2024 | Heplisav-B |
| Curonix LLC | $31.68 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Genentech USA, INC. | $20.74 | 2021 | |
| Irhythm Technologies, INC. | $19.02 | 2024 | Zio Xt Patch, Zio Monitor |
| Axsome Therapeutics, INC. | $17.92 | 2023 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $16.06 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.84 | 2020 | |
| Sanofi Pasteur INC. | $14.82 | 2020 | |
| Medtronic, INC. | $13.95 | 2025 | Closurefast |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.